Work experience in the biotech, pharmaceutical or semiconductor industries is desirable. We are looking for driven, talented Senior Process Engineers to join…From Illumina, Inc. – Wed, 22 Feb 2017 23:53:54 GMT – View all San Diego jobs
This individual will lead teams that provide technical leadership to new product introduction, production process development, improvement and sustaining…From Illumina, Inc. – Wed, 22 Feb 2017 23:53:54 GMT – View all San Diego jobs
Two Managers will be located at San Diego Miramar College and be part of the California Community Colleges Economic and Workforce Development Initiative (http://doingwhatmatters.cccco.edu/Overview/DWMFramework.aspx). The Statewide Sector Navigator wi […
Biotech experience preferred. Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation…From Indeed – Wed, 22 Feb 2017 22:20:55 GMT – View all San Diego jobs
Biotech industry experience. Maintains files of descriptions of available supplies. Is a biopharmaceutical company with a mission to deliver breakthrough…From Indeed – Wed, 22 Feb 2017 22:12:00 GMT – View all La Jolla jobs
Experience with legal filing document program GettingLegalDone.com a plus. Excellent attention to detail and strong planning abilities….From Imprimis Pharmaceutical – Wed, 22 Feb 2017 21:07:12 GMT – View all San Diego jobs
At Pacira Pharmaceuticals, controlling postsurgical pain is the key to improving patient outcomes. Our in-depth knowledge of the needs of the postsurgical pain market, coupled with our passion for delivering improved patient care, drives our commitme […
A local preclinical Contract Research Organization located in Kearny Mesa is seeking candidate for a Research Associate. The Research Associate is responsible for the scheduling and conduct of in-vivo studies involving the testing […
PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company,…
[[Click headline to continue reading.]]
Cancer Immunotherapy Company to Discuss Clinical Translation of PV-001 Dengue/Dendritic Cell Treatment
SAN DIEGO, Feb. 22, 2017 /PRNewswire/ — PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony Chen, will be presenting at the Annual Biocom Global Life Science Partnering Conference. The presentation will take place on March 2, at 11:15 AM, at the Torrey Pines Lodge, in San Diego.
“We are thankful to the organizers at Biocom who have chosen our company, amongst numerous others, to present at this international symposium of biotechnology companies, investors, and clinical researchers,” said Mr. Chen. “In contrast to conferences in previous years, there is an increase in the number of cancer immunotherapy companies presenting. This trend reflects the excitement we observe in the industry where new methods are being tried to fight cancer.”
PrimeVax takes a unique approach to treating cancer by combining virus-induced immune stimulation and dendritic cell therapy. A description of the PrimeVax approach was recently published in the peer-reviewed literature by the company management1.
“With the clinical implementation of various immunotherapeutic strategies, it is becoming more and more apparent that we need to activate multiple arms of the immune system at the same time,” said Santosh Kesari, MD, PhD, Scientific Co-Founder of PrimeVax and Chair of Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute and Pacific Neuroscience Institute. “We are very excited about the progress that Mr. Chen has made in advancing this technology, and I look forward to helping patients suffering from deadly cancers such as melanoma and glioblastoma.”
PrimeVax Immuno-Oncology, Inc. is focused on development of personalized immunotherapy by leveraging its PV-001 platform. The platform enables PrimeVax to develop a 1 time 1 week cancer treatment schedule for many cancer types agnostic of tumor mutation characteristics. PV-001 leverages the body’s innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2017. Initial indications to be targeted are metastatic melanoma, triple negative breast cancer, and glioblastoma.
SOURCE PrimeVax Immuno-Oncology, Inc.